The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution
Duy Nguyen(Harvard University), Bishoy M. Faltas(Cornell University), Cora N. Sternberg(Radboud University Nijmegen), Giorgio Inghirami(New York University), Jenna E. Moyer(Cornell University), Scott T. Tagawa(Cornell University), Ana M. Molina(Cornell University), Jyothi Manohar(Cornell University), Philip H. Abbosh(Fox Chase Cancer Center), William F. Hooper(New York Genome Center), Heather Geiger(New York Genome Center), Jones T. Nauseef(Cornell University), Nicolas Robine(New York Genome Center), Michael Sigouros(Cornell University), Henkel Valentine(Fox Chase Cancer Center), Florencia P. Madorsky Rowdo(Cornell University), David M. Nanus(Cornell University), Jennifer Shelton(Kansas State University), Timothy R. Chu(New York Genome Center), Adrienne Helland(New York Genome Center), Juan Miguel Mosquera(NewYork–Presbyterian Hospital), Andrea Sboner(NewYork–Presbyterian Hospital), Douglas S. Scherr(NewYork–Presbyterian Hospital), Olivier Elemento, Mohamed Osman(Cornell University), Zoe R. Goldstein(New York Genome Center), Weisi Liu(Cornell University), David Wilkes(Cornell University), Rahul Singh(Cornell University), Alissa Semaan(Cornell University), Sandra Cohen(Cornell University), Majd Al Assaad(Cornell University), Minita Shah(New York Genome Center), Lara Winterkorn(New York Genome Center)
Cited by 51
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
|The Lancet|2002|1.7k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k